Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Kim P. C. Kuypers, Livia Ng, David Erritzøe, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1039-1057
Open Access | Times Cited: 169
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 2, pp. 125-139
Closed Access | Times Cited: 145
Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis
Jing-Li Yue, Xiang-Wen Chang, Jun-Wei Zheng, et al.
Sleep Medicine Reviews (2023) Vol. 68, pp. 101746-101746
Closed Access | Times Cited: 49
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
Yves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
Annals of Neurology (2020) Vol. 87, Iss. 3, pp. 347-356
Closed Access | Times Cited: 110
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
Gary Zammit, Yves Dauvilliers, Scott Pain, et al.
Neurology (2020) Vol. 94, Iss. 21
Closed Access | Times Cited: 86
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Synthetic Approaches to the New Drugs Approved During 2022
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4376-4418
Closed Access | Times Cited: 9
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea
Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
SLEEP (2020) Vol. 44, Iss. 6
Open Access | Times Cited: 33
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, et al.
SLEEP (2021) Vol. 45, Iss. 3
Open Access | Times Cited: 31
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Clemens Muehlan, Sander Brooks, Cédric Vaillant, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 6, pp. 1334-1342
Open Access | Times Cited: 20
Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials
Feiyu Jiang, Hang Li, Yanting Chen, et al.
Medicine (2023) Vol. 102, Iss. 7, pp. e32754-e32754
Open Access | Times Cited: 12
Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study
Mariana Fernandes, Fabio Placidi, Nicola Biagio Mercuri, et al.
Neurological Sciences (2024) Vol. 45, Iss. 7, pp. 3443-3448
Open Access | Times Cited: 3
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Clemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 3, pp. 326-335
Closed Access | Times Cited: 29
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Daridorexant in Insomnia Disorder: A Profile of Its Use
Tina Nie, Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 267-274
Open Access | Times Cited: 8
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies
Marie‐Laure Boof, Abir Alatrach, Mike Ufer, et al.
European Journal of Clinical Pharmacology (2018) Vol. 75, Iss. 2, pp. 195-205
Closed Access | Times Cited: 25
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry
Clemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Current Drug Metabolism (2019) Vol. 20, Iss. 4, pp. 254-265
Closed Access | Times Cited: 23
First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 7, pp. 1377-1386
Open Access | Times Cited: 23
Effect of the novel dual orexin receptor antagonist daridorexant on night‐time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease
Marie‐Laure Boof, Jasper Dingemanse, Mareile Brunke, et al.
Journal of Sleep Research (2021) Vol. 30, Iss. 4
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top